Akihiko Gemma

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.5K citations

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo et al. · Annals of Oncology · 2012 · 549 citations

Oncology, Pathology, Cancer Treatment +6

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

Akira Inoue, Kunihiko Kobayashi, Kazuhiro Usui et al. · Journal of Clinical Oncology · 2009 · 515 citations

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers

Masahiro Seike, Akiteru Goto, Tetsuya Okano et al. · Proceedings of the National Academy of Sciences · 2009 · 498 citations · Full text

Engineering, Pathology, Tumor Biology +16